Three-Parent IVF and Other Thin Evidence · Morning Gist
Tuesday, November 35 stories · 14 min
Three-Parent IVF and Other Thin Evidence
An embryo procedure sold on weak data, a chemo surprise in mice, a fatal dairy-linked H5N1 case, and Georgia's Medicaid bill coming due.
Picked from 23 new articles across 12 sources · arrow keys for other days
Today in 30 seconds
30s left
STAT finds three-parent IVF sold abroad to older women; one broker's average patient age rose from 39 to nearly 46, its 54% pregnancy claim unsubstantiated. story 1 ↓
Carboplatin and paclitaxel act like a vaccine adjuvant in mice, an effect that disappears without the T-cell transcription factor TCF-1. story 2 ↓
A Yakima County, Washington resident with prior health conditions died of H5N1 after dairy exposure; the CDC found no viral changes increasing spread or severity. story 3 ↓
Georgia's Medicaid work program may expire; the state says matching federal exemptions could add 100,000 enrollees and $1.4 billion by mid-2028, and wants more federal money. story 4 ↓
A dairy-funded review says natural dairy trans fats don't raise heart risk; Marion Nestle flags the funders and authors' ties, and her post gives no effect sizes. story 5 ↓
1/5STAT· Megan Molteni· Nov 2
Three-parent IVF sold to older women abroad despite scant evidence, STAT finds
STAT found clinics abroad selling three-parent IVF, built to prevent mitochondrial disease, to women in their 40s and 50s as a fertility fix. Available data suggest it rarely helps them; long-term safety is unknown.
Why it matters · It shows how an experimental embryo procedure can reach paying patients through weak journals, conference abstracts and social media, and what to check before trusting a clinic's success rate.
Know this first
Context from the editor, not the article · 28 sec
1 · Mitochondria and their DNA
Mitochondria are the cell's energy producers. They carry a small genome of their own, separate from the chromosomes in the nucleus, and children inherit them almost entirely from the egg. Mutations can cause rare, sometimes fatal diseases.
2 · Eggs, age and chromosomes
As eggs age, the chromosome-halving step before fertilization becomes more error-prone, so embryos can end up with too many or too few chromosomes. This is a major reason IVF success falls with maternal age, especially after 40.
3 · IVF add-ons
Add-ons are extra paid procedures sold as improving the odds of having a baby. They have multiplied in lightly regulated private fertility markets, though large reviews have found the science behind many of them shaky.
2/5In the Pipeline (Derek Lowe)· · Nov 2
Chemotherapy boosts cancer vaccines in mice, via a T-cell gene
In mice, standard chemotherapy made therapeutic cancer vaccines work better, acting like a vaccine adjuvant. The benefit vanished in animals lacking the T-cell gene TCF-1, and adding an anti-PD-1 drug beat every other combination.
Why it matters · If chemotherapy actively primes immune responses rather than blunting them, trial designers can stop treating concurrent chemo as a confound and start sequencing it deliberately.
Know this first
Context from the editor, not the article · 23 sec
1 · Chemo vs immunotherapy
Chemotherapy kills rapidly dividing cells directly. Immunotherapy instead gets the patient's own immune system to attack the tumour. They are often discussed as separate, even competing, treatment strategies.
2 · T cells and tumours
T cells are immune cells that can kill cancer cells they recognise. Tumours defend themselves by recruiting suppressive cells and by switching T cells off through receptors like PD-1.
3 · Therapeutic cancer vaccines
Unlike preventive vaccines, these are given to people who already have cancer, to teach T cells to recognise a tumour protein. The approach has a long history of clinical failure.
3/5STAT· Associated Press· Nov 2
Washington resident dies of H5N1 bird flu after exposure at dairy
A hospitalized Yakima County resident exposed at an infected dairy has died of H5N1, the first U.S. bird flu death in a year. The CDC found no worrying viral mutations and still rates public risk low.
Why it matters · The death shows cattle exposure can precede fatal illness in a person with prior health conditions, while genetic testing so far offers no sign the virus has become more dangerous.
Know this first
Context from the editor, not the article · 27 sec
1 · What H5N1 is
H5N1 is a subtype of avian influenza. The letters and numbers name two proteins on the virus's surface. It has spread widely among wild birds and poultry and has also infected cows and other mammals.
2 · Bird flu in cattle
Infections spread among U.S. livestock in early 2024, raising concern. Dairy herds put the virus close to farm workers, creating a route of human exposure beyond contact with birds.
3 · Why mutations are monitored
Flu viruses change as they copy themselves. Scientists sequence samples from patients to look for changes linked to better spread between people or worse illness, because sustained human transmission is what could turn sporadic cases into a pandemic.
4/5KFF Health News· Briah Lumpkins and Sam Whitehead· Nov 2
Georgia's Medicaid Work Program, a Model for Federal Rules, May Expire
Georgia Pathways, the state's work-tied Medicaid program for about 20,600 people, expires Dec. 31 unless renewed. Georgia says federal rules make it unaffordable without extra money, leaving the next governor to decide its fate.
Why it matters · Washington's answer could reset the financial incentives for limited Medicaid expansions nationwide, and Georgia's enrollment record shows what paperwork-heavy eligibility can look like in practice.
Know this first
Context from the editor, not the article · 29 sec
1 · Medicaid expansion and its funding
The Affordable Care Act let states extend Medicaid to adults earning up to 138% of the poverty level, with Washington paying 90% of their costs. Regular match rates are lower: roughly two-thirds federal in Georgia.
2 · Medicaid waivers
States can run Medicaid outside normal federal rules only with federal approval, usually through time-limited Section 1115 demonstration waivers. That signoff can be slow, contested in court and subject to renewal, which is why such programs can face expiry dates.
A University of Reading-publicized review found dairy trans fats aren't tied to heart disease or type 2 diabetes. Dairy groups funded it, and nutrition professor Marion Nestle argues independent researchers should settle the question.
Why it matters · The claim could shape how dairy fat is regarded, but it rests on industry-funded work, and Nestle's post gives no effect sizes for judging it.
Know this first
Context from the editor, not the article · 29 sec
1 · Two sources of trans fats
Industrial trans fats form when vegetable oils are partially hydrogenated. Ruminant trans fats form naturally when microbes in the stomachs of cows and similar animals hydrogenate unsaturated fats, so they end up in milk and meat.
2 · What is already established
Industrial trans fats raise LDL cholesterol, lower HDL cholesterol and predict more heart disease. Many countries, including the US, have restricted them. Whether the smaller amounts of ruminant trans fats in the diet do similar harm is more contested.
3 · Why funding gets scrutiny
Sponsorship does not make a finding false. But reviews involve judgment calls about which studies to include and how to interpret them, and research on sponsored products has tended to reach conclusions favorable to the sponsor.
SAGA Clinic's FDA-logo sign in Tirana; the agency says registration alone does not signal approval or safety.1 / 4
An eight-month STAT investigation reports that hundreds of women, many in their late 40s or early 50s, have travelled abroad over the past decade for 1, despite almost no evidence that it treats age-related infertility.
What MRT was built for
Mitochondria, the cell's energy producers, carry their own small genome, inherited through the egg. MRT, or "three-parent IVF," moves a patient's nuclear DNA into a donor egg or embryo that keeps its mitochondria. The aim was to stop mothers passing on mitochondrial disease. It is effectively illegal in the US, where Congress bars the FDA from considering such trials. The UK allows it at one clinic, only to prevent disease.
The pitch
The International Fertility Group of North America (IFG), an Illinois 2, or broker, linked clients with clinics such as SAGA in Albania. "With age, egg 'batteries' lose power," one post said. The average patient age in its program rose from 39.2 in 2022 to 45.6 last year. Its website claimed a 54% pregnancy rate per cycle, which nobody substantiated. SAGA says it doesn't collect such data.
Wendy, 46 and Dutch, paid more than $30,000. Of her 11 embryos, two survived MRT to transfer stage. One was genetically abnormal and the other failed to implant.
What the data show
The main age problem is 3, meaning embryos with the wrong chromosome count. MRT carries the patient's own chromosomes across, so it can't fix errors already in them.
Pavlo Mazur, a Ukrainian embryologist, offered 4, a version of MRT done after fertilization, to 19 women aged 36 to 44. Only one ever got an embryo with the right chromosome count. He then put young donors' nuclear DNA into older women's emptied eggs, keeping their old mitochondria: 40% of embryos reached a transferable stage, and 70% of those had normal chromosomes. That suggests old mitochondria weren't the problem. But the work is unpublished, because journals rejected it for lacking patient consent and ethics approval.
The only peer-reviewed infertility study used 5, in which the chromosomes are moved before fertilization. It reported a 31.6% live birth rate per transfer in 25 women under 40, but under 10% for the 12 aged 39.
Embryologist Birol Aydin, who performed Wendy's procedure, and IFG adviser Uliana Dorofeyeva reported 48.3% live births among 27 older patients. Their paper ran in an unindexed journal on whose board she sat, and was accepted in under three weeks. Aydin defends the data.
What changes
IFG paused new MRT patients in July and last week removed MRT from its website, calling that precautionary rather than a finding about its claims. Aydin has stopped performing it. The market may just move, though: IFG is seeking a replacement, and a Bahamas clinic has a growing waiting list for an untested variant.
No controlled trial exists, and long-term safety data on the children would take 20 years or more. For now, women over 40 have no solid evidence that MRT helps them.
STAT has published an eight-month investigation into a for-profit trade in 1, drawing on 45 interviews, private patient-group posts, WhatsApp messages, contracts and business filings. Over the past decade, it reports, hundreds of women have travelled to clinics in Eastern Europe, Mexico, the Bahamas, the Philippines and elsewhere for the procedure, many of them in their late 40s or early 50s. Nobody has a firm birth count; some industry insiders estimate up to 200.
A disease-prevention tool, resold
MRT, popularly "three-parent IVF," puts a patient's nuclear DNA into a donor egg or embryo that keeps its own mitochondria. There are two main forms. In 2, an embryologist uses a polarized-light microscope to find the spindle, the structure that lines up and separates chromosomes during 3, the egg's chromosome-halving division. The spindle is sucked out and placed in an emptied donor egg, which is then fertilized. In 4, the swap happens after fertilization, between the patient's embryo and a donor embryo made with the same man's sperm. Either way, the child has both parents' nuclear DNA and the donor's mitochondrial DNA.
MRT was developed to stop women passing on mitochondrial mutations. A one-sentence 5, adopted by 2015, bars the FDA from even acknowledging trial applications involving modified human embryos, leaving MRT effectively illegal in the US. The UK approves it case by case at a single clinic, at Newcastle University, and only to prevent disease.
The pitch, and one patient
The International Fertility Group of North America (IFG), based near Chicago, is a 6: a broker linking patients with clinics in countries where a procedure is legal. "With age, egg 'batteries' lose power," one of its posts said; another told women over 45 it was not too late. By its own webinar slide, the average patient age in its program rose from 39.2 in 2022 to 45.6 last year. Its website claimed 34 births as of February 2025 and a 54% pregnancy rate for IVF cycles with MRT. No one substantiated that rate. SAGA, the Albanian clinic where most clients went, says it doesn't collect such data. SAGA's FDA-logo sign reflects only registration in an agency database, not approval.
Wendy, a 46-year-old Dutch client, shows how this can play out. She paid more than $30,000, went through three egg retrievals in two countries and reached 11 embryos. After embryologist Birol Aydin performed MRT in November 2025, two survived to transfer stage. One was genetically abnormal; the other failed to implant. No test could show whether her mitochondria were ever the problem. "We are just assuming you may have mitochondrial issue," Aydin texted her.
Why the theory fails for most older women
The central age problem is 7, meaning embryos with the wrong number of chromosomes, which rises through the 30s and spikes after 40. MRT replaces the mitochondria but carries over the patient's own chromosomes and spindle. If the damage is already in that nuclear material, a younger egg's contents can't undo it.
Ukrainian embryologist Pavlo Mazur, who pioneered pronuclear transfer for infertility, saw this at Kyiv's Nadiya Clinic. Among 19 women aged 36 to 44, only one, aged 42, ever obtained a single embryo with the right chromosome count. Of ten babies born through the venture, Darwin Life-Nadiya, nine had mothers 35 or younger.
He then ran the reverse experiment, placing young donors' leftover nuclear DNA into older women's emptied eggs, which kept their older mitochondria. If old mitochondria were the fault, these should have failed. Instead, 40% of the embryos reached a transferable stage, and 70% of those had normal chromosome counts.
The caveat is large: this work isn't peer-reviewed. Mazur presented it as a poster at the American Society for Reproductive Medicine's 2019 meeting, but journals rejected the manuscript because he lacked patient consent and ethics approval for using the leftover eggs.
The competing numbers
In 2023, Aydin and Uliana Dorofeyeva, a Ukrainian fertility doctor who advises IFG, reported a 48.3% live birth rate among 27 older patients, and 33% for those over 42. For comparison, one large study of IVF in women 45 and older found 4.4% per embryo transfer. But the paper appeared in The Journal of Reproduction, which isn't indexed in major repositories. It was accepted in under three weeks, Dorofeyeva sat on the editorial board, and it ran alongside an ad for their egg bank, Ovogene. It also showed no data on donor mitochondria levels in the children. Aydin defends his data, while saying group statistics poorly represent any individual's chances. Mazur, who later took over Aydin's cases, describes the records he found as "a random table with random numbers."
A 2025 abstract from the pair at a 8 meeting claimed rates of 40% or higher among 66 patients with a mean age of 39. Independent scientists said it omitted how many women fell in each age group and how many cycles each had. ESHRE itself opposes commercial MRT.
The only peer-reviewed infertility study, from Shoukhrat Mitalipov of Oregon Health & Science University and Nuno Costa-Borges, reported a 31.6% live birth rate per transfer in 25 patients under 40 in Greece. Its supplement shows under 10% for the 12 patients aged 39, a very small subgroup. Mitalipov told STAT MRT is unlikely to work over 40, though he hasn't tested that. Mary Herbert of Monash University, reviewing the literature for Nature Medicine, calls direct evidence that mitochondrial dysfunction drives the age effect "very, very sparse." Anecdotally, Bay Area specialist Aimee Eyvazzadeh has referred about 50 older patients for MRT without a success yet, though she would still mention it.
IFG's most featured success is confounded. Heidy Willis was 33 when she delivered twins, and her eggs first underwent 9, a hormone culture that prods immature eggs to mature. Aydin says he can't tell which step helped. A 23andMe test also put the girls at 50% Ukrainian ancestry, the donor's background. Willis says she was told this reflected mitochondrial DNA, but 23andMe says its ancestry reports use only nuclear DNA. Aydin blames imprecise consumer tests. The question remains unresolved.
What happens now
IFG paused new MRT patients in July and last week removed MRT from its website, calling that "a precautionary communications decision." It denies any legal relationship with a near-identically named Slovak company owned by Dorofeyeva, who also co-owns SAGA and says she is only a paid IFG consultant. Aydin has stopped performing MRT, saying patients shouldn't pay for an experimental treatment when it's so hard to select who may benefit.
The trade may simply move. IFG offered Mazur the job at a Dominican Republic clinic; he declined. A Bahamas clinic is offering a newer variant using immature eggs, with one reconstructed-embryo success in two patients, no transfers yet and a growing waiting list.
Two questions remain open. Safety is one: Johns Hopkins bioethicist Jeffrey Kahn notes that data on the adult health and fertility of these children would take 20 years or more. Efficacy is the other: no one has run the controlled trials that Harvard's I. Glenn Cohen and others want, including in any younger subgroup that might benefit. Patients told STAT they'd prefer a trial but won't wait for one, and clinics going quiet could mean even less visibility.
Remember
Mazur's unpublished reverse experiment points to the egg's nuclear DNA, not its mitochondria, as the main age problem.
A headline success rate means little without age breakdowns: 31.6% overall in one study fell below 10% at age 39.
An FDA logo at a clinic can mean database registration only, not approval, inspection or endorsement.
Derek Lowe, the chemist who writes the long-running drug discovery blog In the Pipeline, flags a mouse study with a practical message: chemotherapy does not just coexist with cancer immunotherapy, it appears to actively amplify it.
The question
Therapeutic cancer vaccines — injections meant to train a patient's own T cells to recognise tumour proteins — are usually tested in people who are already on chemotherapy. That has long been treated as a confound, or at best a tolerable messiness. But hints of benefit had shown up before, so the authors ran the combination deliberately.
They gave mice 1 (a virus engineered to carry a tumour antigen into cells) together with carboplatin plus paclitaxel, the standard pairing clinicians call 2. The vaccine plus chemotherapy clearly beat the vaccine alone.
Why that is surprising
The existing explanation was timing-based. Chemotherapy kills 3 — a class of immune cells that, inside tumours, often suppress T-cell attack — so clearing them out first should leave a vaccine a cleaner field to work in. Here the two were given at the same time, with no head start. Looking at T cells and myeloid cells, the authors found myeloid depletion is part of the story but not all of it; other mechanisms remain unidentified.
The mechanism they did find
CarboTaxol behaved like an 4 — an ingredient added to vaccines to make the immune response stronger. The effect was not specific to viral-vector vaccines, and not specific to one tumour type.
It did depend on 5, a transcription factor (a protein that switches genes on and off) already known to matter for T-cell development and long-term function. In mice engineered to lack TCF-1, the benefit disappeared.
The effect is also drug-specific: cyclophosphamide reproduced it, gemcitabine did not. So "chemotherapy helps immunotherapy" is not a blanket rule about cytotoxic drugs.
Three drugs at once
A triple combination — vaccine, CarboTaxol and an anti-6 antibody, the checkpoint inhibitor class that releases a brake tumours use to switch T cells off — beat every other combination significantly.
The caveat the authors themselves raise is sequence and timing, already a known variable in chemo-plus-immunotherapy regimens. The goal, as Lowe describes it, is to raise tumour-attacking T-cell numbers, suppress the myeloid and regulatory cells that blunt them, and keep antigen-presenting cells stoking the response. He calls it a tightrope, and suspects the right order will vary by patient.
Two honest limits: this is mouse work, and "significantly more effective" arrives without the numbers. Lowe's conclusion is that the chemotherapy-or-immunotherapy fork is a false one — the answer looks like both.
Derek Lowe, the medicinal chemist behind the long-running drug discovery blog In the Pipeline, has written up a paper whose conclusion runs against a tidy mental model many people hold about cancer treatment: that chemotherapy and immunotherapy are rival philosophies, one poisoning fast-dividing cells, the other recruiting the patient's immune system. The study, done in mice, finds that standard chemotherapy makes a 1 work considerably better — and identifies at least one molecular reason why.
The setup, and why it was worth testing
A therapeutic cancer vaccine is not preventive like a flu shot. It is given to someone who already has a tumour, and its job is to show the immune system a tumour-associated protein so that T cells learn to hunt cells displaying it. The field has a long history of disappointment.
One awkward practical fact about that history: vaccine trials are often run in patients who are simultaneously receiving chemotherapy, because withholding standard care is not an option. That has usually been treated as background noise. But some apparently beneficial interactions had been noticed, so the authors stopped treating the overlap as a nuisance and tested it directly.
They used 2 — a virus engineered to be harmless but to deliver the genetic instructions for a tumour antigen into cells, so the body manufactures and displays it. These were combined with carboplatin plus paclitaxel, a widely used chemotherapy doublet that clinicians shorthand as 3. Compared with the vaccine on its own, adding the chemotherapy was, in Lowe's words, definitely beneficial.
Why the result is not just a restatement of old findings
There was already a story for why chemotherapy might help immunotherapy, and it was about timing. Inside tumours sit 4 — a family of immune cells including macrophages and certain immature cell types that, in a tumour's environment, frequently act as suppressors, damping down T-cell attack rather than supporting it. Chemotherapy depletes myeloid cells. Clear them out, wait, then vaccinate into the cleared space: plausible, and previously observed.
That is not what happened here. The vaccine and the chemotherapy were given simultaneously, with no window for myeloid clearance to precede the immune stimulus. The authors examined both T-cell and myeloid-cell populations and concluded that myeloid depletion is genuinely part of the explanation — but not the whole of it. Other mechanisms are at work, and the paper does not claim to know what they are. That unresolved gap is stated plainly rather than papered over.
The 5 effect, and the gene that carries it
The more interesting finding is that CarboTaxol behaves like an adjuvant. In vaccine science an adjuvant is a component added alongside the antigen whose only job is to make the immune response bigger and more durable — aluminium salts in many conventional vaccines are the familiar example. Chemotherapy, on this reading, is doing adjuvant work.
Two things make that claim broader than a single experiment. The effect was not confined to viral-vector vaccines, so it is not an artefact of how that particular platform delivers antigen. And it was not confined to one tumour type, so it is not a quirk of one cancer model.
The mechanism the authors pin down depends on 6, a transcription factor — a protein that binds DNA and turns sets of genes on or off. TCF-1 is well established in immunology as important both in T-cell development and in how T cells function later, including the maintenance of stem-like T-cell populations that can keep renewing a response rather than burning out. Experiments pointed toward TCF-1, and the decisive test was genetic: in 7 animals, engineered to lack TCF-1 entirely, the improvement vanished. Not diminished — gone. That is the kind of result that converts a correlation into a candidate mechanism.
Crucially, this is not a general property of cytotoxic drugs. Cyclophosphamide reproduced the effect; gemcitabine did not. So the useful statement is not "chemotherapy helps vaccines" but "some chemotherapies do, and which ones is an empirical question." That specificity is a gift for trial design and a warning against over-generalising.
Adding a checkpoint inhibitor
The authors then went to three agents: vaccine, CarboTaxol, and an anti-PD-1 antibody. 8 is a receptor on T cells that functions as an off-switch; many tumours exploit it to shut down an attack that has already begun, and anti-PD-1 drugs — the checkpoint inhibitors that reshaped oncology over the past decade — block that interaction. The triple combination was significantly more effective than any other combination tested.
Lowe reports the authors' own caveat alongside it: order and timing. Sequencing is already known to matter when chemotherapy and immune-directed therapy are combined, and the optimal order here may shift depending on a patient's circumstances. He lays out the competing objectives the regimen has to satisfy at once — increase the number of tumour-attacking T cells, decrease the myeloid and other regulatory mechanisms that would suppress them, and keep antigen-presenting cells active so they continue driving the T-cell response. "It can be a tightrope," he writes.
What to hold onto, and what is missing
Two limits deserve stating. This is mouse work; the vaccine field in particular has a record of mouse results that did not survive the move to humans. And the write-up gives direction without magnitude — "definitely beneficial," "significantly more effective" — so the effect sizes are not available from Lowe's account. A reader wanting to know how much better the triple combination was has to go to the paper.
What the study does supply is a mechanism with a hard genetic test behind it, a dependence on drug identity rather than chemotherapy in general, and an open admission that myeloid depletion alone does not explain the benefit. Lowe's own reading is that the decision point many people imagine — chemotherapy or immunotherapy — is not real: on this evidence, you should do both.
Remember
The benefit depended on TCF-1: in mice lacking that gene, the chemotherapy-plus-vaccine improvement disappeared entirely.
Drug identity matters. Cyclophosphamide reproduced the adjuvant effect; gemcitabine did not. Not all chemotherapy qualifies.
Myeloid cell depletion explains only part of the benefit. The remaining mechanisms are unidentified.
A Yakima County, Washington, resident died Sunday from complications of bird flu after exposure at a dairy with infected cattle, county health officials said. It is the first U.S. bird flu death in a year.
The patient had previous health conditions and had been hospitalized. The 1 identified the virus as 2, a subtype of avian influenza. Officials released no other personal or clinical details.
The local outbreak
County officials report that 33 dairy herds have recently tested positive for H5N1, and they have linked three human infections to dairy exposure. Local and state health departments are finding 3 of those patients and monitoring them for symptoms.
No sign of a more dangerous virus so far
The CDC analyzed the 4 of the patient's virus and found no changes that would make it spread more easily or cause more severe illness. This is reassuring, but sequencing can only flag changes scientists already recognize, and this result comes from one patient.
The CDC says there is no known person-to-person spread and that risk to the general public remains low.
Putting the death in context
This is the third U.S. death tied to bird flu since it became a national concern in 2024. An elderly Louisiana resident with H5N1 died in a case announced in January 2025, and a Washington resident died of 5, a rarer subtype, in November 2025. Public health reports at the time tied those cases to backyard birds, a point the article doesn't address. It also doesn't say whether this is the first U.S. death linked to cattle.
The CDC counts more than 70 reported U.S. human infections since the start of 2024. Three deaths against that total works out to about 4%, but that is not a reliable fatality rate: the numbers are small, one death involved a different subtype, and mild infections can go undetected.
What changes for people
Official advice for the public has not changed. People who work on farms are considered at higher risk. Those in contact with sick or dead birds are urged to wear respiratory and eye protection, and gloves when handling poultry. The article doesn't mention new guidance specific to dairy workers.
Still unknown are how the person was exposed at the dairy, how severe the other two dairy-linked infections were, and whether monitoring of contacts will find more cases.
A resident of Yakima County, Washington, died Sunday from complications of bird flu after being exposed at a dairy with infected cattle, county health officials said. The 1 identified the virus as 2, a subtype of avian influenza. It is the first U.S. bird flu death in a year.
The patient had previous health conditions and had been hospitalized. Officials released no other details, so the public account does not include the person's age, the timing of the illness or the treatment received.
The local outbreak
County officials report that 33 dairy herds have recently tested positive for H5N1. They have linked three human infections to dairy exposure. The Yakima Health District and the state health department are identifying 3 of those patients and monitoring them for symptoms. That work is meant to catch any further infections early, including any that might suggest spread between people. None has been reported.
How this death compares
This is the third U.S. death tied to bird flu since it became a national concern in 2024:
January 2025: an elderly person in Louisiana with H5N1.
November 2025: a person in Washington with 4, a rarer subtype.
November 2026: this Yakima County patient with H5N1.
The article does not make this comparison, but public health reports at the time tied the two earlier deaths to backyard birds. That would make the dairy exposure a notable difference. The AP story does not say whether this is the first U.S. death linked to cattle.
What the sequencing does and doesn't show
The CDC analyzed the 5 of the virus from the patient and found no changes that would help it spread more easily or cause more severe illness, a spokesperson said Monday.
This is reassuring but limited. Sequencing can only flag changes that scientists already recognize as important. It also describes the virus from one patient rather than every virus circulating in the 33 herds. And the finding suggests that the death doesn't need a more dangerous virus to explain it, although the patient's prior conditions may have played a role that the available details can't quantify.
Reading the numbers
The CDC counts more than 70 reported human infections in the U.S. since the start of 2024. There is no known person-to-person spread, and the agency says risk to the general public is low.
Dividing three deaths by about 70 cases gives roughly 4%, but that is only a rough illustration and should not be read as a fatality rate. One of the three deaths involved a different subtype, and the case count is limited to infections that were detected. Mild infections are easy to miss, which would make the true rate lower. Three deaths are also too few to support a stable estimate.
What changes for people
For the general public, the official guidance has not changed. The higher-risk group is people who work on farms. Officials urge anyone in contact with sick or dead birds to wear respiratory and eye protection, and gloves when handling poultry. The article does not describe specific new guidance for dairy workers.
The main open questions are how the patient was exposed at the dairy, whether the other two dairy-linked infections were severe, and whether monitoring finds additional cases among contacts.
Remember
The patient had prior health conditions, and officials have released too little detail to generalize about individual risk.
Three deaths among 70-plus reported infections cannot give a reliable fatality rate, partly because mild cases can go undetected.
Watch whether contact monitoring in Yakima finds new cases, since person-to-person spread would change the risk assessment.
Arkansas imposed Medicaid work rules in 2018. About 18,000 people lost coverage before a court halted them, and a New England Journal of Medicine study found no significant rise in employment. That is observational evidence from one state.
Image: KFF Health News
1, the state's limited 2 program, is slated to expire at the end of this year unless renewed. It partly inspired the work rules reaching most of the country on Jan. 1. Now the winner of Georgia's tight governor's race inherits its fate.
What Pathways is
Medicaid is the joint federal-state insurance program for people with low incomes. The 3 (ACA) lets states extend it to adults earning up to 138% of the 4, the government's income benchmark. That is $45,540 for a family of four in 2026. Forty states and Washington, D.C., have done so.
Georgia instead launched Pathways in 2023. It covers people at or below 100% of poverty ($33,000 for that family) who complete up to 80 hours a month of work, training, community service or similar activities.
Why it's at risk
The 5, President Trump's signature law, created the federal work rules, and they include exemptions Georgia lacks. People who prove they are too sick to work, those with a substance use disorder, and caretakers for people with disabilities can be excused.
Georgia's work rule has limited who can enroll, so loosening it enlarges the pool. State officials estimate about 100,000 more people would qualify, with $1.4 billion in added spending on them by mid-2028. Those are the state's own figures, produced while asking the federal government for more money. A similar request was denied when Pathways was created. Officials have signaled they may let the program lapse without the funding.
Approval could set a precedent. Policy researchers say richer funding for limited programs would weaken the incentive to expand fully and might encourage some states to roll back.
The record
As of Oct. 9, 20,606 people were enrolled, after more than $128 million in combined state and federal spending. The state had projected more than 25,000 after one year. Many find enrollment hard to navigate, and Georgia's benefits portal has a documented history of glitches and slow processing.
The next governor's options
Democrat Keisha Lance Bottoms wants full expansion and would "restructure" Pathways meanwhile, but a 2014 state law requires approval from a legislature whose Republican leaders have long opposed it. Republican Rick Jackson promises "intelligent Medicaid expansion" with few details. Any such alternative would probably need slow federal signoff.
Full expansion could reach an estimated 347,000 uninsured Georgians, according to a left-leaning think tank, but would also move hundreds of thousands off federally subsidized ACA plans. A right-leaning analyst argues even skimpy private coverage offers better access than Medicaid; the article gives no data for that. It also gives no data on Pathways' health outcomes.
Meanwhile, enrollees wait. Trey Wright, 27, says Pathways saves him more than $1,700 a year on allergy shots. He didn't know he might lose it.
1, the state's limited 2 program and a partial model for the work rules arriving across most of the country on Jan. 1, is slated to expire at the end of this year unless it is renewed. The deadline coincides with the end of Gov. Brian Kemp's term, so the decision falls largely to his successor, in a race KFF Health News describes as tight.
How Georgia got here
Medicaid is the joint federal-state insurance program for people with low incomes. Under the 3 (ACA), states can extend it to adults earning up to 138% of the 4, the government's income benchmark for poverty. In 2026, that is $45,540 for a family of four. Forty states and Washington, D.C., have done so.
Kemp pursued a narrower alternative. Pathways covers only people at or below 100% of the poverty level, or $33,000 for that family, who complete up to 80 hours a month of work, workforce training, community service or other qualifying activities. Georgia applied in 2019, but a protracted legal fight delayed the launch until 2023.
The federal work rules come from President Donald Trump's 5, his signature legislation. Starting Jan. 1, enrollees in fully expanded states must show they are working, volunteering or attending school for 80 hours a month. Some states, such as Nebraska, are already enforcing the rules. States that never expanded Medicaid do not have to adopt them.
Why more exemptions mean more cost
Georgia's problem is that the federal version is, in one respect, more lenient than its own. To comply with federal law, Pathways must offer exemptions it doesn't have now. People who prove they are too sick to work would not face the reporting requirements. Other groups can be exempted too, including people with a substance use disorder and caretakers for people with disabilities.
An illustrative case, not one from the article: an adult below the poverty line who cares full time for a disabled relative may have no way to log qualifying hours and so can't get Pathways today. With an exemption, that person could qualify. Georgia's work rule has acted as a gate on enrollment, so loosening it enlarges the eligible pool.
State officials estimate this would bring in about 100,000 more people, roughly five times current enrollment. A state projection puts the additional spending on this group at $1.4 billion by mid-2028. The article does not say how that sum divides between state and federal money. Both figures come from an agency arguing for more federal funding, and the article cites no independent check.
The request to Washington
The Department of Community Health, Georgia's Medicaid agency, has asked the 6 (CMS), the federal agency that oversees Medicaid, for enhanced funding for this group. The article does not give the rate requested. Georgia made a similar request when it applied to create Pathways and was denied.
This time the agency attached a warning. Without the money, officials wrote, "the state will have no alternative but to make decisions that imperil health policy goals around personal responsibility and healthy choices." They have signaled they may let the program lapse. CMS says it doesn't comment on pending requests. Kemp's spokesperson says the governor supports the request.
The answer could matter beyond Georgia. Approval could set a precedent for other states to draw more federal money for limited expansions, adding federal spending. "It's an attractive fiscal offer for states," said Joan Alker, executive director of the Georgetown University Center for Children and Families. Policy researchers say that would weaken the incentive to expand fully and might even encourage some states to roll back their expansions.
Three years of results
The record so far is modest. As of Oct. 9, more than three years in, 20,606 people were enrolled. The state originally projected more than 25,000 after one year. Combined state and federal spending has exceeded $128 million, according to state data obtained through a public records request.
Researchers attribute the low participation partly to an enrollment process many find hard to navigate. 7, the state's online portal for benefits such as Medicaid and food assistance, has a documented history of glitches, errors and slow processing. The state's Medicaid agency declined interview requests and did not answer specific questions about Pathways.
The benefits for those who do get in can be concrete. Trey Wright, 27, of rural Jesup, now sees a primary care doctor regularly, and Pathways covers weekly allergy shots that he says save him more than $1,700 a year. He told reporters he was unaware he might lose coverage by year's end. That is one enrollee's account, not a measure of the program's health effects, and the article offers no outcome data.
What each candidate could actually do
Democrat Keisha Lance Bottoms, a former Atlanta mayor, wants full expansion. Her campaign says she would "restructure" Pathways in the meantime and fix eligibility systems so people aren't denied over paperwork. But a 2014 state law requires legislative approval for expansion, and Georgia's Republican lawmakers have resisted it for years.
Republican Rick Jackson, a healthcare staffing executive, has pitched "intelligent Medicaid expansion" with few details, and his campaign did not respond to questions. Chris Denson of the right-leaning Georgia Public Policy Foundation says an alternative would probably need federal signoff on rule changes, which would take time.
The trade-offs of full expansion
Full expansion could open Medicaid to an estimated 347,000 uninsured Georgians, according to the left-leaning Center on Budget and Policy Priorities. It would also move hundreds of thousands of people out of subsidized ACA plans, whose federal subsidies cost the state nothing. Denson argues that even skimpy private coverage offers better access to doctors than Medicaid, though the article presents no data for that claim.
Advocates read the politics differently. Laura Colbert of the consumer group Georgians for a Healthy Future calls it "almost kind of silly" to keep expansion at arm's length when the federal rules were shaped by Georgia's model. Researchers add a practical doubt: a state struggling to enroll 20,000 people may lack the capacity to sign up far more.
What remains open
The article leaves the central questions unresolved: whether CMS will pay, whether Georgia would really let Pathways lapse, and what would happen to current enrollees if it did. Wright, who works part time, would probably meet the work rules under full expansion, though the transition might not be seamless.
Remember
Georgia's work rule also restricts eligibility, which is why adding federal exemptions could multiply enrollment about fivefold.
Georgia enrolled 20,606 people in over three years, fewer than the 25,000-plus it projected after one.
Even if Democrats win the governorship, full expansion in Georgia still needs legislative approval under a 2014 state law.
A review in the journal Nutrition Research, promoted in a University of Reading press release, concludes that trans fats occurring naturally in dairy foods are not linked to higher risk of heart disease or type 2 diabetes. Marion Nestle, a nutrition scholar at New York University who collects such papers, flagged it on her blog for a different reason: dairy organizations paid for it, and some of the authors work for them.
The question
Industrial trans fats, made by 1 vegetable oils (adding hydrogen to harden them), clearly raise heart disease risk. Cows and other ruminants produce trans fats too, through microbes in their stomachs. Nestle notes that these differ in some ways from the industrial kind but are still trans fats. If they were shown to be harmless, dairy would escape one of the charges against it.
What the review reports
The paper combines a 2 and 3 of randomized controlled trials, which pools results from experiments, with a systematic review of 4, which follow people over time. Its stated highlights are:
Dairy enriched with trans fats and regular dairy showed no differences in 5, such as blood fat measurements.
Blood levels of dairy trans fats showed no association with type 2 diabetes or cardiovascular disease.
Nestle's post gives no effect sizes, 6, doses or study counts, so the size and precision of these results can't be judged from it.
The conflicts
The US National Dairy Council and 7, the French dairy trade organization, funded the work. Two authors work for CNIEL and one for the National Dairy Council. Two others have received dairy-industry funding.
Nestle argues the question "would be easier to resolve if the investigators doing the research were independent." She notes that opposing advocates, such as the Physicians Committee for Responsible Medicine, argue that dairy fats do raise risk.
How to read it
Beyond the funding, the highlights themselves suggest limits (this is our reading, not Nestle's). Lipid changes are stand-ins for heart disease, not heart attacks themselves. Cohort associations can be 8 and cannot establish cause, so the paper's title, which says dairy trans fats "do not affect" risk, goes further than "no association" can support.
The claim also covers only trans fats. Dairy fat is mostly saturated fat, which this finding doesn't address, so it gives no reason on its own to change how you eat.
A review published in Nutrition Research (2026;150:33–48) carries a blunt title: "Trans fatty acids from dairy foods do not affect risk of cardiometabolic diseases." A University of Reading press release summarizes it as showing that naturally occurring dairy trans fats are not linked to higher risk of heart disease or type 2 diabetes, "distinguishing them from industrial trans fats."
Marion Nestle, a nutrition scholar at New York University, added the paper to her running blog series on industry-funded studies. Her objection is to who did the work. She does not reanalyze the data, and her post is short, so what follows separates what it reports from background and our own reading.
Why the question exists
Trans fats are unsaturated fats with a particular chemical shape. Most dietary trans fats come from two sources.
Industrial trans fats are created by 1, a process that adds hydrogen to vegetable oil to harden it. Their harm is about as well established as anything in nutrition. Nestle says they "demonstrably raise the risk of heart disease." An often-cited 2006 analysis in the New England Journal of Medicine estimated about 23% more coronary heart disease for each 2% of daily energy from trans fats, and the US and many other countries have since restricted them.
2 trans fats form in cows, sheep and goats, whose stomach microbes partially hydrogenate the unsaturated fats the animals eat. Those fats then reach milk and meat. Nestle says they differ in some ways from industrial trans fats "but are still trans fats."
The difference is partly chemical, since the two sources contain different mixtures of trans fat molecules. It is also a matter of dose, which makes the question hard to study. As a rough illustration, a tablespoon of butter contains about half a gram of trans fat. The World Health Organization advises keeping all trans fat below 1% of energy, about 2.2 grams on a 2,000-calorie diet. Typical intake from dairy can therefore be low enough that any harm would be difficult to detect, and that difficulty doesn't by itself show safety at any given dose.
What the review did
The paper combines two kinds of evidence:
A 3 and 4 of randomized controlled trials, in which studies are searched for by predefined rules and their results statistically pooled. According to the highlights, these trials compared dairy enriched with trans fats against regular dairy and found no differences in , the blood fat measurements used to gauge cardiovascular risk.
From these, the authors conclude that trans fats from dairy foods are "not associated with adverse cardiometabolic outcomes."
Nestle's post gives no effect sizes, 7, trial doses, participant numbers or counts of included studies. Those details are what would show whether "no difference" means a tight estimate near zero or an imprecise result that can't rule out meaningful harm. The post also doesn't describe how the authors assessed study quality.
The funding and the authors
The declarations quoted in the post are specific:
Funders: the US National Dairy Council and 8 (Centre National Interprofessionnel de l'Economie Laitière), the French dairy trade organization.
Employees: two authors work for CNIEL and one for the National Dairy Council.
Grant recipients: one author has received research funding from Dairy Management, Inc., and another from various international dairy organizations.
Nestle describes the paper as "a literature review funded by the dairy industry and conducted by employees or recipients of research funding from dairy companies or trade associations." She argues the industry has a direct stake, since it "would like to prove that dairy fats do not raise the risk of heart disease." She says opposing groups such as the Physicians Committee for Responsible Medicine, which she describes as an animal welfare group, argue that dairy fats do raise risk. "Hence, this review," she writes, adding that the question "would be easier to resolve if the investigators doing the research were independent."
Her critique concerns conflict of interest and does not identify a specific error in the methods or the numbers. Funding is a reason for closer scrutiny, not proof that the conclusion is wrong. It matters here because reviews depend on judgment calls, such as which studies to include and how to treat uncertain results.
What the highlights can and can't show
The following points are our reading of the summary, not claims from Nestle or the paper:
The trials measure stand-ins. The trial highlight concerns lipid biomarkers. It says nothing about heart attacks or strokes, and blood lipids capture only part of how a food might affect risk.
The cohort evidence is observational. Blood levels of dairy trans fats partly reflect how much dairy someone eats, along with other diet and health habits that can confound the results. These studies can show an absence of association but can't establish absence of effect.
The title outruns the highlights. "Do not affect" is causal language. "No association" and "no lipid biomarker differences" are narrower claims.
Null results depend on precision. Without the intervals, a reader of the post can't tell how much harm the data exclude.
What changes for patients
Nothing in this post justifies a change in diet. The finding concerns one small component of dairy fat. Dairy fat is mostly saturated, and the highlights don't address saturated fat, or whether whole dairy foods are good or bad for the heart. The practical message about industrial trans fats also stays the same.
The post leaves open whether the review's numbers hold up, and whether independent researchers would reach the same conclusion. Answering the first needs the full paper, including its intervals and study-quality ratings. Answering the second needs the independent work Nestle is asking for.
Remember
Natural and industrial trans fats have different sources and mixtures, but the evidence of harm is far stronger for industrial ones.
A null result means little without its confidence interval, which separates a precise near-zero estimate from one that can't exclude harm.
The title says "do not affect," but cohort data showing "no association" cannot establish that causal claim.
A systematic review of 6, which follow people over time. Here the highlight is that circulating dairy trans fats, meaning levels measured in blood, showed no association with type 2 diabetes or cardiovascular disease.
